Aim: Lectin-like oxidized LDL receptor-1 (LOX-1) is a class E oxidized LDL specific scavenger receptor that recognizes multiple ligands. Advanced glycation end products (AGEs) have been recently identified as other ligands to LOX-1 and shown to increase LOX-1 expressions in diabetes; therefore, we investigated the underlying mechanism involved. Methods: Confluent human aortic endothelial cells were treated with a fixed concentration of AGE-BSA or BSA as a control in the presence or absence of either antibody of the receptor for advanced glycation end products, mammalian target of rapamycin (mTOR) inhibitor rapamycin, NF-kB inhibitor, phosphoinositide 3-kinases (PI3K) inhibitor or anti-diabetic drug metformin. After stimulation, cells were lysed and Western blot protein expression on LOX-1, rapamycin-insensitive companion of mTOR (RICTOR), the phosphorylation status of p-mTOR, p-P70S6 kinase and p-Akt were determined. 41% (p＜0.05) and LOX-1 expression by 61.5% (p＜0.01) . Knockdown of RICTOR by RNA silencing showed a 41.5% (p＜0.01) and 71.2% (p＜0.01) reduction in LOX-1 and p-Akt expressions, respectively. Preincubation of endothelial cells with AGE-BSA and metformin, an anti-diabetic drug known to have an mTOR inhibition effect, significantly reduced AGEstimulated LOX-1 expression. Conclusion: Our results indicated that LOX-1 up-regulation induced by AGE-BSA was a receptor mediated through RAGE and is via the PI3K/PDK1/mTORC2 pathway. Metformincan reduce AGE-stimulated LOX-1 expression in endothelial cells in vitro.
Introduction
LOX-1 is a recently cloned class E oxidized LDL specific scavenger receptor that is predominantly expressed in endothelial cells, macrophages and vascular smooth muscle cells 1) . LOX-1 is a type Ⅱ glycolmembrane protein spanning 50 kDa in size and con-was prepared by sequential ultracentrifugation 26) . Oxidized LDL was prepared by incubating freshly prepared LDL (1 mg/mL) with 5 μM CuCl2 in 0.1 mol/ L phosphate-buffered saline (PBS) in the dark for 16 h at 37 ℃. Native LDL was used as a control and was prepared by incubating LDL with 1 mM EDTA and 1 mM DTPA for 16 hours. The modification was stopped by extensive dialysis of the reaction mixture against 0.15 M NaCl and 1 mM EDTA at 4 ℃ 27) .
Cell Culture
Human aortic endothelial cells (HAEC) (Clonetics, San Diego, CA) were grown to confluence in EGM-1 Bullet Kit Medium and passages 5-8 were used throughout the experiments. Confluent human aortic endothelial cells were kept overnight in serumfree, supplement-free EGM-1 medium and subse-ways including p38 (MAPK), p44/42 MAPK, protein kinase C (PKC) and transcription factor NF-kB [5] [6] [7] [8] . This results in increased expression of adhesion molecules and monocyte chemoattractant protein-1 9) , release of matrix metalloproteinases, and reduction of endothelial nitric oxide synthase expression 10, 11) . In vascular smooth muscle cells, ligation of oxLDL to LOX-1 has been reported to induce apoptosis 12) and in macrophages, uptake of oxLDL by LOX-1 leads to foam cell formation 13) .
LOX-1 is not constitutively expressed and the expression of LOX-1 can be induced by a number of stimuli including oxLDL 14, 15) , shear stress 16) , inflammatory cytokines [17] [18] [19] and angiotensin Ⅱ 20) . We and other groups have shown that AGEs can also induce LOX-1 expression 17, 21) . Since there is increased formation and accumulation of AGEs in diabetes mellitus, AGEs may contribute to the increased expression in LOX-1 seen in human diabetes 17, 22) . In contrast to oxLDL, which has been shown to induce LOX-1 expression via activation of NF-kB 14) , the intracellular signaling pathways involved in AGEs-stimulated LOX-1 expression have not been delineated. In the present study, we have shown that, unlike oxLDL, pretreatment with NF-kB inhibitor does not reduce AGEs-induced LOX-1 expression. This would suggest that stimulation of LOX-1 expression by AGEs is not mediated via activation of NF-kB. On the other hand, rapamycin, an inhibitor of the mammalian target of rapamycin (mTOR), can markedly reduce AGEsstimulated LOX-1 expression in endothelial cells in vitro. We have further elucidated the role of mTOR signaling in the regulation of LOX-1 expression in AGE-stimulated endothelial cells, and examined the effect of metformin, an anti-diabetic drug that has an mTOR inhibition effect 23, 24) , on AGE-stimulated LOX-1 expression.
Methods

AGE-BSA Preparation
AGE-BSA was prepared by incubating 20 mg/ mL BSA (fraction V, low endotoxin; Invitrogen) with 0.5 M glucose in PBS, pH 7.2, at 37 ℃ under sterile conditions. After 90 days of incubation, unbound lowmolecular-weight products were removed by extensive dialysis against PBS. The degree of glycation on BSA (AGE-BSA fluorescence) was measured by spectrofluorometric detection at excitation of 370 nm and emission of 440 nm 25) .
Low-Density Lipoprotein Isolation and Modification
Low-density lipoprotein (d = 1.02-1.05 g/mL) 
Western Blot Analysis
After stimulation, HAEC cells were washed and scraped in ice-cold PBS. After lysis in RIPA buffer, cells were further sonicated and cell supernatants were quantified by the Lowry protein assay (Biorad, Hercules, CA, USA). Then, 25 ug protein of total cell lysates was electrophoresed on 7.5% SDS-polyacrylamide gel followed by immunoblotting onto a polyvinylidene difluoride membrane (PVDF). The membrane was subsequently probed against primary antibodies specific to LOX-1 (1:1000; R&D), RICTOR, RAPTOR, and mTOR (1:1000; Cell Signaling, MA). To determine the phosphorylation status of AGE-treated endothelial cells, phospho-specific antibodies (1:1000; Cell Signaling) of p-mTOR(Ser2448), p-P70S6 (Thr389) (substrates of mTORC1 complex) and p-Akt (Ser473) (substrates of mTORC2 complex) underwent Western blot analysis as shown above. Secondary antibody of anti-rabbit IgG (1:2500) conjugated with horseradish peroxidase (HRP) was then applied to the membrane before X-ray film autoradiography. Betaactin was employed for standardization. All experi-quently treated with a fixed concentration of 100 μg/ mL AGE-BSA in the presence or absence of mTOR inhibitor rapamycin, phosphoinositide 3-kinases (PI3K) inhibitor (LY294002), NF-kB inhibitor (BAY11-7085), metformin (Calbiochem, Rockland, MA, USA), antibody of receptor for advanced glycation endproducts, anti-RAGE (R&D, MN) or siRNA (on RICTOR or RAPTOR; Ambion, Grand Island, NY, USA).
Transfection of siRNA
RICTOR, regulatory associated protein of mTOR (RAPTOR) and scrambled control siRNA were purchased from Ambion. HAEC cells were transfected with 100 nM siRNA in Optimem medium (Invitrogen, Grand Island, CA, USA) mixed with Lipofectamine 2000 according to the manufacturer's instructions. After six hours of transfection, cells were starved for 12 hours and finally HAEC cells were treated with the indicated AGE-BSA concentrations for another six hours. A B downstream targets of both mTORC1 and mTORC2 were also evaluated. AGE-BSA increased the phosphorylation of p-mTOR (1.4-fold±0.1, p＜0.05), and predominantly the downstream target of mTORC2, p-Akt (2.6-fold±0.3, p＜0.05) and had a lesser effect on the downstream target of mTORC1, p-P70S6 kinase (1.3-fold±0.1, p＜0.05) (Fig. 4A) . Rapamycin, a specific mTOR inhibitor, was used in our experiments to inhibit the mTOR pathway. As expected, incubating endothelial cells with AGE-BSA in the presence of rapamycin down-regulated the level of protein expressions of p-mTOR, p-Akt and p-P70S6K ( Fig. 4A) . This resulted in a reduction of LOX-1 expression by 61.5% compared to AGE-BSAtreated cells as a control (p＜0.01) ( Fig. 4B) . Taken together, these data would suggest that AGE-BSA increased LOX-1 in HAEC cells via phosphorylation of the mTOR pathway. Unlike AGE-BSA, incubating endothelial cells with oxLDL in the presence of rapa-ments were repeated 3 to 5 times and the results are expressed asthe mean±SD.
Results
Both AGE-BSA and oxLDL induced LOX-1 expression in HAEC cells but, unlike oxLDL, the effect of AGE-BSA on LOX-1 expression was not blocked by NF-kB inhibitor (Fig. 1) . Adding AGE-BSA to endothelial cells led to a dose-and timedependent increase in LOX-1 expression ( Fig. 2) . To investigate whether the upregulation of LOX-1 by AGE-BSA was mediated by the mTOR pathway, AGE-BSA was added to endothelial cell culture and phosphorylation of p-mTOR was measured. Our data showed that AGE-BSA stimulated the phosphorylation of p-mTOR in a dose-and time-dependent manner ( Fig. 3) . Since mTOR forms two distinct functional complexes, termed mTORC1 and mTORC2, ＊ p＜0.05 versus BSA-treated cells, and # p＜0.05, ## p＜0.01 vs AGE-BSA-treated cells. Rapamycin blocked AGE-BSA induced LOX-1 expression but had no effect on oxLDL-induced LOX-1 expression (4C). ＊ p＜0.05 versus native LDLtreated cells. C also performed using RAPTOR or RICTOR siRNA to inhibit mTORC1 or mTORC2, respectively. RIC-TOR and RAPTOR siRNA specifically blocked RIC-TOR and RAPTOR expression while control siRNA had no effect (Fig. 5C) . Western blotting showed that RICTOR siRNA significantly decreased both LOX-1 expressions by 41.5% (p＜0.01) ( Fig. 5D ) and p-Akt by 71.2% (p＜0.01) ( Fig. 5E) , whereas no changes were observed with RAPTOR siRNA.
To investigate whether upstream activation of the mTOR pathway by AGE-BSA is receptor-mediated by the receptor for advanced glycation end products (RAGE), HAEC cells were pretreated with anti-RAGE antibody (R&D, MN) 1 hour prior to AGE-BSA incubation.Blocking RAGE activation with AGE-BSA led to a 58.4% reduction (p＜0.05) in the level of phosphorylation of p-mTOR ( Fig. 6A) and a 33.3% mycin showed no reduction of LOX-1 expression, indicating that the mTOR pathway is not involved in the activation of LOX-1 by oxLDL in endothelial cells (Fig. 4C) .
To further delineate whether AGE-BSA upregulates LOX-1 mainly via mTORC1 and/or mTORC2, we measured the expression of RAPTOR and RIC-TOR, the two associated binding proteins of mTORC1 and mTORC2, respectively. Incubation of endothelial cells with AGE-BSA had no significant effect on RAPTOR expression whereas RICTOR expression was significantly increased by 2.2-fold± 0.3, p＜0.05. Treatment of rapamycin prior to AGE-BSA stimulation of HAEC showed a marked reduction of RICTOR protein expression by 66.7% (p＜ 0.05) (Fig. 5A) , but had no significant effect on RAP-TOR protein expression ( Fig. 5B) . Experiments were Fig. 5 . AGE-BSA induced LOX-1 expression in HACEs mainly via mTORC2. HACEs were incubated with 100 ug/mL AGE-BSA for 6 hours and Western blot analysis showed an increase in RICTOR expression (5A) but no similar increase in RAPTOR expression (5B). The increase in RICTOR expression was abolished by the addition of rapamycin (1 uM). ＊ p＜0.05 versus BSA control and # p＜0.05 vs AGE-BSA-treated cells. 5C) HAECs were transfected with RAPTOR, RICTOR or CONTROL siRNA. Western blot analysis confirmedtheefficiency of knockdown 48 hours after transfection. ## p = 0.01 versus AGE-BSA-treated cells. 5D and 5E) Transfected HAECs were incubated with 100ug/ml AGE-BSA for 6 hours. Knockdown of RICTOR, but not RAPTOR, reduced LOX-1 and p-Akt expressions ( ＊ p＜0.05, ＊ ＊ p＜0.01 versus BSA-treated cells, ## p＜0.01 vs AGE-BSA-treated cells). RAGE and activation of the mTOR pathway. Since metformin is an anti-diabetic drug known to have an inhibitory effect on mTOR signaling, we therefore investigated whether metformin can attenuate the effect of AGEs on LOX-1 expression in endothelial cells. Our data showed that AGE-BSA increased RAGE expression by 1.4-fold (p＜0.05) and adding metformin did not change RAGE expression in AGEstimulated endothelial cells; however, the addition of metformin reduced p-mTOR by 41.4% (p＜0.01) and decreased LOX-1 expression by 61.5% (p＜0.01) in these cells (Fig. 8) .
Discussion
Diabetes is associated with a high risk of atherosclerosis and recent evidence suggests that the scaven-(p＜0.01) reduction in LOX-1 expression compared to AGE-BSA-treated cells asacontrol (Fig. 6B) .
Since ligation of RAGE is known to activate PI3K 28) , experiments were performed to determine whether RAGE-mediated mTOR activation is via PI3K. HAEC cells were treated with LY294002 (a PI3K inhibitor) 1 hour before AGE-BSA stimulation. This resulted in a decrease in the expression level of p-PDK1, a downstream effector molecule of the PI3K pathway, by 36.3% (p＜0.05) (Fig. 7A) , and a reduction in the phosphorylation level of p-mTOR by 56.8% (p＜0.01) (Fig. 7B) . This was accompanied by a 43.4% (p＜0.01) reduction in LOX-1 expression compared to AGE-BSA-treated cells as a control (Fig. 7C) .
Our data have so far shown that AGEs induced LOX-1 expression in endothelial cells via binding to C that mTOR has a role in cardiac hypertrophy 31) and cardiovascular-related disorders such as atherosclerosis 32) , and our data add to the body of evidence implicating mTOR in atherosclerosis. mTOR exists in two different protein complexes, mTORC1 and mTORC2, which have distinct physiological functions and are regulated by different mechanisms. mTORC1 is composed of mTOR, RAP-TOR, mLST8 and PRAS40 and regulates a number of major cellular processes including nutrient metabolism, ribosome biogenesis, and mRNA translation. mTORC2 consists of mTOR, mLST8, sin1, RIC-TOR, Protor and PRR5 and is found to regulate Akt activity and cytoskeleton arrangement [33] [34] [35] . Rapamycin is an mTOR inhibitor and recent data suggest that the inhibition of mTORC1 and mTORC2 by rapamycin may be dose-and time-dependent. Rapamycin interacts with the intracellular receptor FK506 binding protein 12 (FKBP12), forming a complex with high affinity for mTOR, and preferentially disrupts mTORC1 activity. At higher concentrations of rapamycin, there is FKBP12-independent suppression of ger receptor LOX-1 may be involved in the process of atherogenesis in diabetes. Immunohistochemical analysis of diabetic rat aorta sections and human atherosclerotic plaques showed distinct elevated LOX-1 staining and provided evidence to suggest that LOX-1 expression is increased in the vasculature 29, 30) . We have previously demonstrated that both LOX-1 and soluble LOX-1 expression in endothelial cell culture can be upregulated by AGEs in vitro 21) . Our current data suggest that mTOR is a critical signaling molecule involved in the upregulation of LOX-1 by AGEs, as the increase in LOX-1 is abolished by use of the mTOR inhibitor rapamycin. mTOR is a conserved serine/threonine kinase that regulates cell cycle progression, protein translation, metabolism, and cellular proliferation. There is growing evidence indicating Fig. 8 . Effect of metformin on AGE-BSA-stimulated LOX-1 expression in HAECs. HAECs were pretreated with metformin (2 mM) for 1 hour before incubation with AGE-BSA (100 ug/mL) for 6 hours. Metformin had no effect on RAGE expression in AGE-BSA-treated cells (8A) but inhibited AGE-BSA-induced p-mTOR (8B) and LOX-1 expression (8C). ＊ p＜0.05 versus BSA control and ## p＜0.01 vs AGE-BSA-treated cells. ureas or insulin. The vasoprotective role of metformin is largely independent of its hypoglycemic action and has been partly ascribed to the beneficial effect of metformin on body weight and plasma lipids. In addition, it has been reported that metformin has favorable pleiotropic effects on the cardiovascular system 40, 41) .
In conclusion, the receptor RAGE, PI3K and mTORC2/RICTOR are involved in the regulation of AGE-induced LOX-1 expression in endothelial cells ( Fig. 9) . AGEs bind to their specific receptor RAGE, activate the PI3K/PDK1/mTORC2 signaling pathway and thereby induce LOX-1 expression. The induction of LOX-1 by AGEs may contribute to the increased atherosclerotic risk in diabetes and this process can be inhibited by metformin in vitro.
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